Skip to content

Hantavirus Nephropathy in North-Eastern France : Severity Risk Factors and Prognostic Tools

Hantavirus Nephropathy in North-Eastern France : Severity Risk Factors and Prognostic Tools

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05415904
Acronym
HANTA-NE
Enrollment
101
Registered
2022-06-13
Start date
2022-05-20
Completion date
2024-07-31
Last updated
2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hantavirus Infection, Hantavirus Nephropathy

Keywords

Acute kidney injury, Hantavirus infection, Hantavirus nephropathy

Brief summary

Hantaviruses are emerging pathogens responsible for hemorrhagic fever with renal syndrome. Severity risks factors aren't consensual in litterature, mostly related to scandinavian cohorts. A prognostic score was created to help patient's orientation in healthcare system but wasn't independantly validated (Hentzien, Emerging infectious diseases 2018). This retrospective cohort of hantavirus infected hospitalized adults patients in the north-eastern quarter of France between 2013 and 2022 will specify the kidney damage during infection and risk factors for a severe form (defined par acute kidney injury KDIGO 3). The previous prognostic score performance will be evaluated in this cohort.

Interventions

OTHERHANTA-NE

Observational cohort study

Sponsors

Central Hospital, Nancy, France
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 125 Years
Healthy volunteers
No

Inclusion criteria

* hantavirus proven by serology infection * age above 18 years * Hospitalisation

Exclusion criteria

* age under 18 years * fulfill opposition form

Design outcomes

Primary

MeasureTime frameDescription
Creatinin levelThrough study completion, an average of 2 yearsAcute Kidney injury KDIGO 3
Hemorrhagic syndromeThrough study completion, an average of 2 yearsMajor bleeding requiring blood transfusion
DeathThrough study completion, an average of 2 yearsDeath
Hospitalisation in intensive care unitThrough study completion, an average of 2 yearsHospitalisation in intensive care unit

Secondary

MeasureTime frameDescription
ALAT, ASATThrough study completion, an average of 2 yearsLiver cytolysis
calciumThrough study completion, an average of 2 yearshypocalcemia, hypercalcemia
phosphorusThrough study completion, an average of 2 yearshypophaspahtaemia, hyperphasphatemia
potassiumThrough study completion, an average of 2 yearshypokaliemia, hyperkaliemia
Score performance to predict severityThrough study completion, an average of 2 yearsCorrelation between severity predicted by the score and bio-clinical severity during hospitalization. Score composition : Hematuria = 7 Visual disorders = 8 Leucocyte count \> 10 x 10\^9 cells/L = 9 Nephrotoxic drug exposure (NSAID, iodinated contrast media, diuretics, renin angiotensin aldosterone system inhibitors, aminoglycosides, glycopeptides) = 10 Thrombocytopenia \< or = 90 000/mm3 = 11 Risk group according score scale 0-10 Low risk 11-19 intermediate risk 20-45 high risk
bicarbonate blood levelThrough study completion, an average of 2 yearsmetabolic acidosis, metabolic alcalosis
HeamoglobinThrough study completion, an average of 2 yearsAnemia
platelets levelThrough study completion, an average of 2 yearsthrombocytemia
Urine outputThrough study completion, an average of 2 yearsPolyruria above 3 L/day
sodiumThrough study completion, an average of 2 yearsblood sodium level disorders
HypotensionThrough study completion, an average of 2 yearsLowest systolic blood presure during hospitalisation \< 90mmHg
ProteinuriaThrough study completion,an average of 2 yearsProteinuria during hospitalisation defined by proteinuria/creatininuria above 500 mg/g or equivalent
Urinary dipstickThrough study completion, an average of 2 yearsLeucocyturia or hematuria

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026